Učitavanje...
Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer
With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment str...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Chinês |
| Izdano: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-04-01
|
| Serija: | Chinese Journal of Lung Cancer |
| Teme: | |
| Online pristup: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.07 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|